Analysts Set Expectations for BEAM FY2025 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Beam Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will post earnings of ($3.48) per share for the year. Cantor Fitzgerald currently has a “Hold” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.64) per share.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.01). Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The firm had revenue of $14.30 million for the quarter, compared to the consensus estimate of $14.52 million. During the same period in the previous year, the business posted ($1.22) earnings per share. The business’s revenue for the quarter was down 16.9% compared to the same quarter last year.

Other equities analysts have also issued research reports about the stock. Leerink Partnrs upgraded shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Wedbush restated an “outperform” rating and set a $57.00 target price on shares of Beam Therapeutics in a report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Beam Therapeutics in a report on Monday, December 9th. Royal Bank of Canada reduced their price objective on Beam Therapeutics from $27.00 to $24.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 6th. Finally, Leerink Partners raised Beam Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $27.00 to $39.00 in a research report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $47.67.

Beam Therapeutics Stock Down 1.2 %

Shares of BEAM stock opened at $25.98 on Thursday. The stock has a 50-day simple moving average of $26.34 and a 200 day simple moving average of $25.75. The stock has a market capitalization of $2.15 billion, a P/E ratio of -14.76 and a beta of 1.92. Beam Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $49.50.

Institutional Trading of Beam Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in BEAM. Charles Schwab Investment Management Inc. increased its holdings in shares of Beam Therapeutics by 6.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 629,492 shares of the company’s stock valued at $15,423,000 after acquiring an additional 36,226 shares during the last quarter. Bank of Montreal Can bought a new position in shares of Beam Therapeutics in the second quarter valued at approximately $3,683,000. Bellevue Group AG lifted its stake in shares of Beam Therapeutics by 7.1% in the third quarter. Bellevue Group AG now owns 1,518,121 shares of the company’s stock worth $37,194,000 after buying an additional 100,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Beam Therapeutics by 4.5% in the third quarter. Geode Capital Management LLC now owns 1,807,683 shares of the company’s stock worth $44,297,000 after buying an additional 78,102 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Beam Therapeutics by 59.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,552,829 shares of the company’s stock worth $87,044,000 after buying an additional 1,328,414 shares during the period. Institutional investors and hedge funds own 99.68% of the company’s stock.

Insider Activity at Beam Therapeutics

In related news, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now owns 102,968 shares of the company’s stock, valued at approximately $2,541,250.24. The trade was a 1.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Giuseppe Ciaramella sold 51,110 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $26.36, for a total transaction of $1,347,259.60. Following the completion of the sale, the president now owns 109,150 shares of the company’s stock, valued at $2,877,194. This represents a 31.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.